Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

NCT ID: NCT04604652

Last Updated: 2024-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-27
• Study Completion Date: 2022-05-31

Brief Summary

The purpose of this open-label study is to evaluate the safety and tolerability of HDT1801 (BUDCA) over 12 weeks in adult subjects with PBC who have an inadequate response to standard therapy. Inadequate response is defined as persistently elevated serum alkaline phosphatase at greater than or equal to1.5 times the upper limits of normal for the testing lab in spite of having been on adequate doses of standard therapy with UDCA (ursodeoxycholic acid) at 13-15 mg/kg for at least 6 months.

Conditions

Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Cholangitis; Cholestasis; Biliary Tract Diseases; Bile Duct Stricture

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open-label

HTD1801 (BUDCA) 250 mg tablets. Dosed at 1000 mg BID with food.

Group Type: EXPERIMENTAL

HTD1801 (BUDCA)

Intervention Type: DRUG

HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.

Interventions

HTD1801 (BUDCA)

HTD1801 (BUDCA) 250 mg tablets. Dose 1000 mg twice daily with food for 12 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Have a clinical diagnosis of PBC as confirmed by patient history consistent with the American Association for the Study of Liver Diseases (AASLD) Practice Guideline confirmed by two of the following three criteria:

1. Biochemical evidence of cholestasis with elevation of ALP activity

2. Presence of antimitochondrial antibody (AMA)

3. Histopathologic evidence of non-suppurative cholangitis and destruction of small or medium-sized bile ducts if biopsy performed Note: historical AMA and liver biopsy data may be used but must be recorded in source documentation.

• Has been taking a stable, adequate dose of at least (13-15 mg/kg/day) of UDCA for at least 6 months with a serum ALP of at least ≥1.5 × ULN at any time after being on UDCA for >6 months (historical value) and at Screening. If the historical ALP was obtained less than 6 months prior to study start as part of standard of care, the subject may be screened and a second ALP value should be obtained as part of screening, There must be at least a 4-week interval between the ALP values and the ALP values must be ≥1.5 × ULN
• If the subject is taking cholestyramine or other bile acid sequestrant for pruritus, must be on a stable dose no more than once a day for at least 8 weeks prior to Baseline visit. Must be willing and able to take cholestyramine at least 2 hours before or after study medication
• Females of child-bearing potential and males participating in the study must either agree to use at least two approved barrier methods of contraception or be completely abstinent from sexual intercourse, if this is their usual and preferred lifestyle, throughout the duration of the study and for three months after stopping study drug. Females who are postmenopausal must have appropriate documentation
• Able to provide consent

Exclusion Criteria

• Uncontrolled concomitant autoimmune hepatitis (AIH). Subject should be on no more than 5 mg per day of prednisone (or equivalent dose for other corticosteroids) or no more than 150 mg per day of azathioprine at stable doses and serum ALT should be ≤ 5 × ULN. Enrollment of subjects with controlled AIH will be limited to a total of 5 subjects.
• History of alcohol or substance abuse
• Prior liver transplantation or currently listed for liver transplantation
• History of chronic viral hepatitis, types B or C
• Platelet count ≤150,000/mm3, albumin <3.0 g/dL, International Normalized Ratio (INR) >1.2, or a history of ascites, or encephalopathy, or history of variceal bleeding
• Total bilirubin >1.3 × ULN unless subject has Gilbert Syndrome. If subject has increased total bilirubin due to Gilbert's Syndrome, then direct bilirubin should be <0.3 mg/dL.
• Hemoglobin <10 g/dL for males or females
• Serum TSH level <0.1 or >10 u/mL (subject may be re-screened if hyper- or hypothyroidism has been corrected)
• Renal impairment with eGFR <60 ml/min (CKD stages 3, 4 or 5)
• Human immunodeficiency virus (HIV)-1 or HIV-2 infection by history
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency
• History of malignancy within the past 2 years or ongoing malignancy other than basal cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma
• Active, serious infections that require parenteral antibiotic or antifungal therapy within 30 days prior to Screening
• Major surgical procedure within 30 days of Screening or prior solid organ transplantation
• Females who are pregnant or breastfeeding
• Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic agents, and immune-modulating agents (such as interleukins, interferons)
• Diseases that may result in increased serum ALP activities from sources other than the biliary system (e.g., Paget's disease of bone, osteomalacia)
• Allergy to the clinical trial material or its components
• Having received any experimental medications within 28 days prior to Screening
• Use of bezafibrate or fenofibrate within 28 days prior to first day of IP dosing
• Use of obeticholic acid (OCA) within 28 days prior to first day of IP dosing
• Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

HighTide Biopharma Pty Ltd

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adrian DiBisceglie, MD

Role: STUDY_DIRECTOR

HighTide Therapeutics Biopharma Pty.

Locations

University of Miami Schiff Center for Liver Disease

Miami, Florida, United States

Piedmont Healthcare

Atlanta, Georgia, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Henry Ford Health Services

Detroit, Michigan, United States

St. Louis University

St Louis, Missouri, United States

Northshore University Hospital

Manhasset, New York, United States

University GI

Providence, Rhode Island, United States

Baylor Research Institute

Dallas, Texas, United States

The Texas Liver Institute

San Antonio, Texas, United States

Liver Institute of Virginia

Newport News, Virginia, United States

Bon Secours Liver Institute of Richmond

Richmond, Virginia, United States

Liver Institute Northwest

Seattle, Washington, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

HTD1801.PCT013

Identifier Type: -

Identifier Source: org_study_id